- The deal is expected to close in early July
- Emmes’ clients include National Institutes of Health, Food and Drug Administration, Department of Defense and Department of Health and Human Services
- Rothschild & Co and Baird served as financial advisors to Emmes on the transaction
New Mountain Capital will acquire CRO Emmes from Behrman Capital. No financial terms were disclosed.
Emmes is a CRO that provides its clients with expertise in biostatistics, technologies and dedicated service required to manage clinical research studies.
On the deal, Dr. Christine Dingivan, president and CEO of Emmes, said in a public statement. “We are excited to partner with the New Mountain team in this next phase of growth. Over the past several years, our executive team has worked diligently to expand our commercial and global presence. We are confident that New Mountain’s growth-oriented investment approach will allow us to continue on this trajectory.”
Rothschild & Co and Baird served as financial advisors to Emmes on the transaction while Goodwin Procter served as its legal advisor. Ropes & Gray served as legal advisor to New Mountain on the transaction.
Founded in 1977, Emmes is a global, full-service CRO focused on the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical, and medical device companies throughout the world.